Home  |  Contact

UniProtKB/Swiss-Prot Q8N1G0: Variant p.Pro937Arg

Zinc finger protein 687
Gene: ZNF687
Variant information

Variant position:  937
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Proline (P) to Arginine (R) at position 937 (P937R, p.Pro937Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (P) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In PDB6; enhances nuclear localization; increases expression levels; R-937 containing osteoclasts induced by treatment of peripheral blood mononuclear cells with CSF1 and TNFSF11 exhibit a greater number of nuclei, as well as a larger surface area than did those from the control individuals.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  937
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1237
The length of the canonical sequence.

Location on the sequence:   PATEESSSSSEEEEVPSSPE  P PRPAKRPRRELGSKGLKGGG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PATEESSSSSEEEEVPSSPEPPRPAKRPRR-ELGSKGLKGGG

Mouse                         PATEESSSSSEEE-LPSSPEPPRPTKRARRGELGNKGIKGG

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1237 Zinc finger protein 687
Cross 954 – 954 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)


Literature citations

ZNF687 mutations in severe paget disease of bone associated with giant cell tumor.
Divisato G.; Formicola D.; Esposito T.; Merlotti D.; Pazzaglia L.; Del Fattore A.; Siris E.; Orcel P.; Brown J.P.; Nuti R.; Strazzullo P.; Benassi M.S.; Cancela M.L.; Michou L.; Rendina D.; Gennari L.; Gianfrancesco F.;
Am. J. Hum. Genet. 98:275-286(2016)
Cited for: VARIANTS PDB6 ILE-242 AND ARG-937; SUBCELLULAR LOCATION; DEVELOPMENTAL STAGE; TISSUE SPECIFICITY; CHARACTERIZATION OF VARIANT ARG-937;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.